[1]王 意,李子珊,雷 雯,等.HPV E6/E7 mRNA检测对HPV16/18 DNA阳性患者的分流价值[J].医学信息,2024,37(18):57-64.[doi:10.3969/j.issn.1006-1959.2024.18.010]
　WANG Yi,LI Zi-shan,LEI Wen,et al.Shunt Value of HPV E6/E7 mRNA Detection in HPV16/18 DNA Positive Patients[J].Journal of Medical Information,2024,37(18):57-64.[doi:10.3969/j.issn.1006-1959.2024.18.010]
点击复制

HPV E6/E7 mRNA检测对HPV16/18 DNA阳性患者的分流价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年18期
页码:
57-64
栏目:
论著
出版日期:
2024-09-15

文章信息/Info

Title:
Shunt Value of HPV E6/E7 mRNA Detection in HPV16/18 DNA Positive Patients
文章编号:
1006-1959（2024）18-0057-08
作者:
王 意1; 李子珊1; 雷 雯2; 黄淑君2; 彭 盼3
1.广东省妇幼保健院妇女保健科，广东 广州 511400；2.广东省妇幼保健院妇女儿童健康研究所，广东 广州 511400；3.广州市宝创生物技术有限公司，广东 广州 51140
Author(s):
WANG Yi1; LI Zi-shan1; LEI Wen2; HUANG Shu-jun2; PENG Pan3
1.Department of Maternal Health Care,Guangdong Maternal and Child Health Hospital,Guangzhou 511400,Guangdong,China;2.Institute of Women and Children’s Health,Guangdong Maternal and Child Health Hospital,Guangzhou 511400,Guangdong,China;3.Guangzhou Baochang Biotechnology Co., LTD.,Guangzhou 511400,Guangdong,China
关键词:
HPV E6/E7 mRNA; HPV; TCT; 高级别鳞状上皮内瘤变
Keywords:
HPV E6/E7 mRNA; HPV; TCT; High-grade squamous intraepithelial lesion
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2024.18.010
摘要:
目的 探讨HPV E6/E7 mRNA对HPV16/18 DNA阳性患者的分流价值。方法 收集127例HPV16/18 DNA阳性的核酸样本，行HPV E6/E7 mRNA检测，并结合宫颈液基细胞学（TCT）结果和病理诊断结果进行统计分析。结果 ①HPV E6/E7 mRNA检出型别以单一感染为主，占比81.93%。年龄分布显示呈双峰状。②HPV E6/E7 mRNA总阳性率为65.35%，且随着宫颈病变程度升高，HPV E6 /E7 mRNA阳性率升高。且LSIL组与炎症组，HSIL+组与炎症组阳性率比较，差异有统计学意义（P＜0.05)。③对HPV 16/18 DNA阳性者，用细胞学进一步分流，可以减少65.35%的阴道镜检查，漏诊44.83%的HSIL+；采用HPV E6/E7 mRNA进行分流，可以减少34.65%的阴道镜检查，漏诊10.34%的HSIL+；HPV E6/E7 mRNA分流漏诊率低于TCT分流方法，差异有统计学意义（P＜0.05)。④HPV16/18 DNA阳性且细胞学检查为≥ASC-US的患者，经HPV E6/E7 mRNA分流，可减少11.36%的阴道镜检查，无漏诊HSIL+。结论 HPV16/18 DNA阳性者进一步用TCT联合HPV E6/E7 mRNA进行同步分流，可以减少阴道镜检查，同时降低≥ASC-US的患者漏诊HSIL+的风险。
Abstract:
Objective To investigate the value of HPV E6/E7 mRNA in the shunt of HPV16/18 DNA positive patients.Methods A total of 127 cases of HPV16/18 DNA positive nucleic acid samples were collected, and HPV E6/E7 mRNA was detected. The results were statistically analyzed in combination with the results of thinprepcytologic test (TCT) and pathological diagnosis.Results ①The HPV E6/E7 mRNA was detected by mainly single infection, accounting for 81.93%. The age distribution showed a bimodal shape. ②The total positive rate of HPV E6/E7 mRNA was 65.35%. With the increase of cervical lesions, the positive rate of HPV E6/E7 mRNA increased, while the positive rate of LSIL group and inflammation group, HSIL+ group and inflammation group was statistically significant (P<0.05). ③As the HPV 16/18 DNA positivity triage test, Cytology at the ASC-US+ threshold could reduce colposcopy by 65.35%, but missed diagnosis of HSIL+ by 44.83%; whereas HPVE6 /E7 mRNA could reduce the colposcopy by 34.65% ,and missed diagnosis of HSIL+ by 10.34%. As a triage test in HPV 16/18 DNA positivity patients, the missed diagnosis rate of HPV E6/E7 mRNA was lower than that of TCT （P＜0.05). ④As a triage test, in patients with HPV16/18 DNA positive and cytological grades ≥ASC-US, E6/E7 mRNA could reduce the colposcopy by 11.36% and none missed diagnosis of HSIL+. Conclusion TCT combined with HPV E6/E7 mRNA for synchronous shunt in HPV16/18 DNA positive patients can reduce colposcopy and the risk of missed diagnosis of HSIL+ in patients with ≥ASC-US.

参考文献/References:

[1]中国优生科学协会阴道镜和宫颈病理学分会专家委员会.中国子宫颈癌筛查及异常管理相关问题专家共识(一)[J].中国妇产科临床杂志,2017,18(2):190-192.[2]Perkins RB,Guido RS,Castle PE,et al.2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors[J].J Low Genit Tract Dis,2020,24(2):102-131.[3]Hu SY,Zhao XL,Zhang Y,et al.Interpretation of "WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention， second edition"[J].National Medical Journal of China,2021,101(34):2653-2657.[4]Wang R,Guo XL,Wisman GB,et al.Nationwide prevalence of human papillomavirus infection and viralgenotype distribution in 37 cities in China[J].BMC Infect Dis,2015,15:257.[5]Zhao X,Zhao S,Hu S,et al.Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China[J].Infect Dis,2019,219(2):215-222.[6]魏丽惠.在中国实施子宫颈癌多元化筛查的策略[J].中国妇产科临床杂志,2015,16(1):1-2.[7]Sharma B,Lakhanpal V,Singh K,et al.Evaluation of HPV E6/E7 mRNA Detection in Clinically Suspected Cases of Cervical Cancer with Abnormal Cytology: Time to Upgrade the Screening Protocols[J].Lab Physicians,2022,14(3):336-342.[8]Origoni M,Cristoforoni P,CarminatiG,et al.E6/E7 mRNA testing for human papilloma virus-induced highgrade cervical intraepithelial disease (CIN2/CIN3): a promising perspective[J].Ecancermedicalscience,2015,9:533.[9]Coquillard G,Palao B,Patterson BK.Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA[J].Gynecol Oncol,2011,120(01):89-93.[10]Breitenecker G.Cervical cancer screening: past--present--future[J].Pathologe,2009,30 Suppl 2:128-35.[11]Karlsen F,Muturi M,Muyabwa C,et al.The potential of RNA as a target for national screening of pre-cancer[J].J Public Health Afr,2018,9(3):866.[12]Weston G,Dombrowski C,Harvey MJ,et al.Original research: Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation[J].BMJ Open,2020,10(3):e031303. [13]Bruno MT,Ferrara M,Fava V,et al.HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women[J].Virol J,2018,15(1):52.[14]Pérot P,Biton A,Marchetta J,et al.Broad-Range Papillomavirus Transcriptome as a Biomarker of Papillomavirus-Associated Cervical High-Grade Cytology[J].J Mol Diagn,2019,21(5):768-781.[15]潘学景,任琛琛,杨立,等.HPV E6/E7 mRNA检测对ASCUS患者分流管理的随访研究[J].现代妇产科进展,2019,28(5):359-362.[16]李晓林,刘莹,范俊,等.hrHPV E6/E7 mRNA检测用于宫颈癌联合筛查的横断面研究[J].现代妇产科进展,2016,25(10):739-743.[17]刘孝敏,韩丽萍,孙嘉敏,等.宫颈癌临床筛查方法探究[J].肿瘤基础与临床,2019,32(5):405-409.[18]Monsonego J,Cox JT,Behrens C,Sandri M,et al.Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S.screening population: data from the ATHENA trial[J].Gynecol Oncol,2015,137:47-54.[19]Benevolo M,Vocaturo A,Caraceni D,et al.Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test[J].J Clin Microbiol,2011,49(7):2643-2650.[20]王富伟,魏爱婷,郭风涛.人乳头状瘤病毒E6/E7mRNA检测对分流人乳头状瘤病毒16/18阳性病人的临床评价[J].中国卫生检验杂志,2017,27(10):1445-1447.[21]Li L,Zhang Q,Chen Y,et al.Role of E6/E7 mRNA in discriminating patients with high-risk human papilloma virus-positive associated with cytology-negative and atypical squamous cells of undetermined significance[J].Biomedical Research (India),2017,9(28):3986-3990.

相似文献/References:

[1]刘洪波,祁晓莉,乔 星,等.HPV分型检测联合TCT检查在宫颈病变筛查中的应用[J].医学信息,2018,31(08):152.[doi:10.3969/j.issn.1006-1959.2018.08.053]
　LIU Hong-bo,QI Xiao-li,QIAO Xing,et al.Application of HPV Typing Test Combined with TCT Examination in Screening Cervical Lesions[J].Journal of Medical Information,2018,31(18):152.[doi:10.3969/j.issn.1006-1959.2018.08.053]
[2]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者 分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
　NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Journal of Medical Information,2018,31(18):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[3]邬素珍,许焕英.宫颈人乳头瘤病毒感染的免疫研究进展[J].医学信息,2018,31(19):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
　WU Su-zhen,XU Huan-ying.Progress in Immunization of Cervical Human Papillomavirus Infection[J].Journal of Medical Information,2018,31(18):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
[4]朱 军,张振君.妇女宫颈病变筛查分析[J].医学信息,2019,32(01):139.[doi:10.3969/j.issn.1006-1959.2019.01.043]
　ZHU Jun,ZHANG Zhen-jun.Screening Analysis of Cervical Lesions in Women[J].Journal of Medical Information,2019,32(18):139.[doi:10.3969/j.issn.1006-1959.2019.01.043]
[5]刘琳琳,宫 正,杨海嵘,等.宫颈癌的诊治及预防研究[J].医学信息,2021,34(03):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
　LIU Lin-lin,GONG Zheng,YANG Hai-rong,et al.Research on Diagnosis,Treatment and Prevention of Cervical Cancer[J].Journal of Medical Information,2021,34(18):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
[6]邵景萍.HPV联合TCT检测在宫颈疾病筛查中的应用[J].医学信息,2022,35(10):168.[doi:10.3969/j.issn.1006-1959.2022.10.043]
　SHAO Jing-ping.Application of HPV Combined with TCT in Cervical Disease Screening[J].Journal of Medical Information,2022,35(18):168.[doi:10.3969/j.issn.1006-1959.2022.10.043]
[7]李明明,赵 芳,张亚青.TCT、HPV联合阴道镜检测在早期宫颈癌及癌前病变筛查中的应用价值[J].医学信息,2023,36(13):103.[doi:10.3969/j.issn.1006-1959.2023.13.020]
　LI Ming-ming,ZHAO Fang,ZHANG Ya-qing.Application Value of TCT, HPV Combined with Colposcopy in the Screening of Early-stage Cervical Cancer and Precancerous Lesions[J].Journal of Medical Information,2023,36(18):103.[doi:10.3969/j.issn.1006-1959.2023.13.020]
[8]见永康,吴泽俊,庄雅丽.宫颈癌筛查联合阴道镜活检防治宫颈癌前病变的价值研究[J].医学信息,2023,36(16):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]
　JIAN Yong-kang,WU Ze-jun,ZHUANG Ya-li.Study on the Value of Cervical Cancer Screening Combined with Colposcopy Biopsy in the Prevention and Treatment of Cervical Precancerous Lesions[J].Journal of Medical Information,2023,36(18):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]

更新日期/Last Update: 1900-01-01